leisure time -WSS

leisure time

author：leisure time 2025-10-01 14:59:55 - browse：46962

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Biden's 'march

entertainment

hotspot

focus

WSS

3 hurdles to bringing medical devices to the U.S. market

First over

$1 billion proposal to grow Boston, Massachusetts biotech

Pregnant women don't need prenatal multivitamins, study concludes

Why are elite athletes different? Take a look at their microbes

The strategy behind pharma's lawsuits over drug pricing reform

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Anesthesiologist group: stop taking Ozempic before surgery

Why are elite athletes different? Take a look at their microbes

Dobbs anniversary: the lost opportunity of abortion as health care

Families look for replacement for GSK asthma drug Flovent

Sports medicine is finally prioritizing gender equality

Biden's 'march

Activists slam private health insurers over coverage restrictions

Why we need to separate burnout from moral injury in health care

Drug repurposing or repositioning? The language matters

Medicare drug price negotiation hearing pits pharma v Biden admin

Wikipedia

Immune cells and nerve overgrowth may explain recurring UTI pain

Microsoft's Peter Lee: Generative AI could help doctors be more human

Medicare drug price negotiation hearing pits pharma v Biden admin

State of the Union pitch: Bigger Medicare drug price negotiations

Gene therapy has helped boys walk. Can scientists keep it that way?

Colonoscopy at 40? Study finds a possible benefit

entertainment

hotspot

focus

entertainment